Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KBLP-005
- Development stage
- Preclinical
- Lead developer
- KoBioLabs
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
KBLP-005 is a microbiome-based therapeutic candidate under development by the South Korean biotechnology company, KoBioLabs, Inc. It is being investigated for immuno-oncology indications. [1, 2, 3] The drug's modality is described as a Live Biotherapeutic Product (LBP), an effector molecule, and potentially a microbe-based Drug Delivery System (mDDS). [1, 2, 3] KoBioLabs is leveraging its proprietary Smartiome technology platform to discover and develop KBLP-005, which is currently in the research and candidate selection phase. [2, 3] The therapeutic is based on microbiome strains with immune-enhancing properties, aiming to improve the effectiveness of standard cancer treatments. [1]
Beyond the preview
Go deeper on KBLP-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KBLP-005.